Chemotherapy‐induced thrombocytopenia (CIT) is a common event in cancer care. Romiplostim has been studied and shown to be an effective therapy for treatment of CIT, although not yet approved by the FDA for this indication. We review the current evidence for romiplostim for CIT.
All Keywords
【저자키워드】 Chemotherapy, thrombocytopenia, Romiplostim, Thrombopoietin receptor agonists, peptibody, platelet growth factors,
【저자키워드】 Chemotherapy, thrombocytopenia, Romiplostim, Thrombopoietin receptor agonists, peptibody, platelet growth factors,